← Eichor
Study identifier: NCT07033572 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma

Condition: Thyroid Neoplasms · Carcinoma, Papillary  ·  Sponsor: Fujian Medical University

PhaseNA
Planned participants60
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

This study evaluates a thyroid-function-preserving alternative to routine total thyroidectomy for bilateral papillary thyroid carcinoma (PTC). Eligible adults undergo remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI dissection on the dominant side, followed by ultrasound-guided radiofrequency ablation (RFA) of a ≤7 mm contralateral focus during the same anesthesia. Outcomes include structural-recurrence-free survival, endocrine-function preservation, safety, and quality of life over 24 months.

This description comes directly from the study's public registry record.

Talk to the study team

Bo Wang Professor, MD  ·  +13959123550  ·  wangbo@fjmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Fujian Medical University Union HospitalFuzhou, Fujian, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07033572